GlaxoSmithKline has announced that the Australian Therapeutic Goods Administration (TGA) has approved the Incruse Ellipta umeclidinium DPI for the treatment of COPD. Incruse Ellipta was approved in Canada and in Europe in April 2014 and in the US in May 2014.
GSK Associate Medical Director Navin Singh said, “We are delighted by the TGA approval of Incruse Ellipta, our first LAMA, which will provide healthcare professionals with a further treatment option for appropriate COPD patients. GSK continues to be committed to developing a range of new therapeutic options that will enable physicians to make treatment choices based on individual patient needs.”
Read the GSK press release.
